Positive Clinical Data from Netherton Syndrome Study
Quoin Pharmaceuticals (QNRX) announced positive interim data from its ongoing pediatric Netherton Syndrome clinical study of QRX003, a topical...
Pasithea Opens EU Clinical Trial Sites & Completes Cohort 4 Dosing
Pasithea Therapeutics, a clinical-stage biotechnology company, has expanded its Phase 1 clinical trial of PAS-004, a next-generation MEK inhibitor,...
First Participants Randomized in AskBio Phase II Gene Therapy Trial for Parkinson’s Disease
AskBio, a Bayer subsidiary, has initiated a Phase II clinical trial, REGENERATE-PD, for its Parkinson’s disease gene therapy, AB-1005...
HMNC Brain Health Completes Patient Randomization for Phase 2b OLIVE Trial for Major Depressive Disorder
HMNC Brain Health has completed patient randomization for its Phase 2b OLIVE trial, investigating the efficacy and safety of...
Totus Medicines Announces Successful Phase 1 Tos-358 Trial & Appoints New CMO
Totus Medicines initiated an expansion study for TOS-358, a first-in-class covalent PI3Kα inhibitor, after a successful Phase 1 trial....
Immunis Secures $25M in Series A-1 Funding
Immunis, Inc., a clinical-stage biotech company, secured $25 million in Series A-1 funding to advance two Phase 2 clinical...
Sage Therapeutics Unveils 2025 Strategic Focus at JPM Healthcare Conference
Sage Therapeutics announced its 2025 strategic focus, centering on the growth of ZURZUVAE (zuranolone) for postpartum depression (PPD) and...
Brain-Computer Interface Tech: Nvidia Holoscan Advancements
Synchron, a brain-computer interface (BCI) company, is partnering with NVIDIA to enhance its implantable BCI technology using the NVIDIA...
Ashvattha Therapeutics Secures $50M, Unveils Promising Phase 2 Ophthalmology Results
Ashvattha Therapeutics secured up to $50 million in extended Series B funding, led by Tribe Capital and existing investors...
Artelo Biosciences Announces Successful Completion of First Cohort in Phase 1 Study of ART26.12
Artelo Biosciences has initiated a Phase 1 clinical trial of ART26.12, its lead FABP5 inhibitor, marking the first time...